Systematic Review and Meta-analysis of Diagnostic and Prognostic Studies: a Tutorial

Marcos R. de Sousa1,2 and Antonio Luiz P. Ribeiro1,2
Servirio de Cardiologia do Hospital das Clinicas da Universidade Federal de Minas Gerais (UFMG), Programa de Pós-Graduação (Doutorado) em Clinica Médica da Faculdade de Medicina da Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG - Brazil

Summary
Systematic reviews with meta-analysis of studies on diagnostic tests or prognostic factors are research tools that are still being developed. The objective of the present paper is to describe the methodology of systematic review and meta-analysis of this type of studies, step by step. A literature review on the subject was made, the recommendations were compiled and the paper was organized in:

a) Introduction,

b) Details on the eight steps to be followed,

c) Form of publication of a systematic review with meta-analysis, and

d) Conclusion.

The systematic review methods were thoroughly described with a critical analysis of the methods of statistical compilation of results, with emphasis on the utilization of the Summary Receiver Operator Characteristic curve. References for the details of each statistical technique used were provided in the meta-analysis. We concluded that systematic reviews with meta-analysis of diagnostic tests or prognostic factors are useful in data compilation of various studies on the same subject, since they reduce biases and increase the statistical power of the primary research.

Introduction
A systematic review of the literature is a planned review of the scientific literature using systematic methods to identify, select and critically analyze relevant studies on a clearly formulated question. The purpose of the systematization is to reduce possible biases that would occur in a non-systematic review1, both for the biases observed in the form of a literature review and in the selection of manuscripts, and those detected by the critical analysis of each study. Meta-analysis is a statistical method used in systematic reviews to integrate the results of the studies included and to increase the statistical power of the primary research. Although some meta-analyses had been published in 1904 and 19552, the term meta-analysis was first used by Glass in 1976 to describe the statistical analysis of the results of analyses of many individual studies with the purpose of integrating their findings3. Sometimes the term meta-analysis is used as a synonym for systematic review, when the review includes meta-analysis4. Although occasionally used as synonyms, metanalysis and meta-analysis have different definitions. Metanalysis is a linguistic resource that signifies the non-etymological breaking down of a word, locution or enunciation that was interpreted by the speakers in a meaning not original to it.

Studies on diagnostic and prognostic tests are old in the medical literature; however, the application of statistical methodology to diagnostic tests and prognostic evaluation tests was developed after its application in therapeutic studies5. Likewise, the standardization of the form of publication of diagnostic studies6 occurred almost a decade after the same process had occurred with therapeutic studies5. The main statistical concepts that are essential in the study of diagnostic methods and prognostic evaluation are listed in Figure 1 and will be used in the text that follows.

There are significant differences between meta-analyses of therapeutic intervention studies which have already been addressed in published handbooks, and meta-analyses of prognostic factors or diagnostic tests which are more recent and less standardized than the first ones5. Meta-analyses of studies comparing interventions or treatments usually include randomized studies with two similar groups assessing the same intervention, in general compared with placebo or with a conventional treatment. Meta-analyses of studies on prognostic factors or diagnostic tests, in turn, face different challenges, such as different cut-off points for the positive or negative result of a test, or assessment of tests that were performed in prospective studies for the analysis of therapeutic interventions. In the 1990’s, new statistical techniques of combination of studies on diagnostic tests were developed6,11. Since 1994, when a guideline for meta-analysis of studies on diagnostic tests12 was published, several different publications with criticisms and propositions on specific aspects of each stage of the process came up. The use of meta-analysis for diagnostic and prognostic tests is still being developed, but it has become increasingly more important1,3,8.

The objective of this review is to summarize the literature available in order to define a tutorial for the performance, step by step, of a systematic review and, if appropriate, of the
Review Article

Sousa & Ribeiro
Meta-analysis of diagnostic and prognostic studies

Figure 1 - Concepts and accuracy measurements of a diagnostic or prognostic test; Every clinical decision is based on probability, whether consciously or not: Diagnosis tests can be used to evaluate the presence or absence of disease, to evaluate the severity of the clinical manifestations, to monitor the response to an intervention, and to estimate the prognosis; a - number of true-positive results (TP); b - number of false-positive results (FP); c - number of false-negative results (FN); d - number of true-negative results (TN); Specificity (E) - probability of a negative test in non-diseased individuals; Sensitivity (S) - probability of a positive test in diseased individuals; Test accuracy: proportion of correct results; Negative predictive value (NPV) - probability of non-occurrence of disease in individuals who test negative; Positive predictive value (PPV) - probability of disease in individuals who test positive; p: in the formula of predictive values, it means prevalence of the disease in the population; Likelihood ratio of a positive test (LR+): measures how much more likely it is for a test to be positive in diseased individuals in comparison with non-diseased individuals; Likelihood ratio of a negative test (LR−): measures how much more likely it is for a test to be negative in diseased individuals in comparison with non-diseased individuals; True-positive rate (TPR) - total number of positive tests in diseased individuals; False-positive rate (FPR) - total number of positive tests in non-diseased individuals; ROC curve: Receiver Operator Characteristic curve. It is used to compare a test with a continuous result to the "gold-standard" or to an endpoint: It is a scatterplot where the y axis = sensitivity (TPR) and the x axis = 1-specificity (FPR); The highest point in the north-west rectangle of the plot is the ideal point of test accuracy, with sensitivity = 100% and specificity = 100%; DOR: diagnostic odds ratio – difficult to be clinically interpreted, but very useful from the statistical point of view in the assessment of the overall test accuracy and also very useful in meta-analysis, because it helps construct the sROC curve (summary ROC, pooled results of various studies in the form of an ROC curve).

Table 1 - Steps for systematic reviews and meta-analyses

<table>
<thead>
<tr>
<th>Step</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Define clearly the question to be formulated.</td>
</tr>
<tr>
<td>2.</td>
<td>Search all reliable studies addressing the question in different sources.</td>
</tr>
<tr>
<td>3.</td>
<td>Select the studies by means of clear inclusion and exclusion criteria, and evaluate the quality of these studies.</td>
</tr>
<tr>
<td>4.</td>
<td>Extract data from each study and display them clearly.</td>
</tr>
<tr>
<td>5.</td>
<td>Evaluate heterogeneity among the studies.</td>
</tr>
<tr>
<td>6.</td>
<td>Calculate the results of each study (and combine them, if appropriate), estimating diagnostic accuracy.</td>
</tr>
<tr>
<td>7.</td>
<td>Assess the effect of variation in study validity on the estimates of diagnostic accuracy.</td>
</tr>
<tr>
<td>8.</td>
<td>Interpret the results, assessing how much of the review and/or meta-analysis can be generalized according to the patients' characteristics.</td>
</tr>
</tbody>
</table>

Define clearly the question to be formulated

Specify clearly the diagnostic or prognostic index test, the disease of interest, how the diagnosis was made, and the context within which the question was formulated. The index test is usually compared with a gold standard for the diagnosis of the disease; however, the statistical methods used for meta-analysis of diagnostic tests may have a wider application\(^\text{13}\). In the case of prognostic tests, these can be evaluated by the death endpoint, response to treatment, or, theoretically, any dichotomous variable of interest regarding the long-term prognosis\(^\text{13}\). Also, clarify whether a test comparison will be performed\(^\text{12}\).
Search all the reliable studies addressing the question in different sources

It is recommended that the search sources are widened as much as possible. Search in governmental publications, ethics commissions, abstracts in annals of congress, theses, and in electronic databases (MEDLINE, EMBASE, LILACS, etc.). In addition to the sources of study search, it is important to consult the Cochrane review library (www.bvs.br) in order to verify whether a given review has already been made. Even when unpublished data are not used, the contact with researchers of ongoing or unpublished studies may be important. For MEDLINE database searching, specify clearly the literature search procedure with the search terms cited, with explicit inclusion and exclusion criteria. The research method with search terms may interfere with the sensitivity of the systematic review. It is important to search MeSH (Medical Subject Headings) descriptors, which is the English vocabulary used for indexing articles (available at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=mesh), to help in the research. The best strategy is usually obtained by the combination of the MeSH terms used with textwords. For studies on prognostic markers, the association of the research subject with the terms (incidence OR mortality OR follow-up studies OR prognos* OR predict*) is suggested in order to increase sensitivity. Make it clear how the literature review process was made (Figure 2).

Publication bias is the tendency of studies with positive results to be more frequently published than studies with negative results, especially in major journals and in the English language. This commonly occurs because both authors and editors show a resistance to publish studies with negative results. Studies with very small samples have a greater chance of publication bias, and this is why some authors recommend their being excluded.

![Figure 2 - Article search and selection process](image-url)
To reduce the possibility of publication bias, the search sources should be widened as much as possible. A search method of therapeutic intervention studies that is difficult to be applied to diagnostic or prognostic test studies is to verify the existence of studies registered, but not published, in ethics commissions or in governmental registers (for instance, www.clinicaltrials.gov), and look for their results. Another source that can be used is abstracts from annals of congress, where studies presented but not published can be accessed.

A statistical means of evaluating publication bias is the use of the funnel scatterplot, inverted funnel or “Christmas tree” (funnel plot). The premise of this plot is that sample size is the strongest correlate of publication bias (Graph 1). Symmetry may be objectively evaluated by means of statistical methods. An asymmetrical shape suggests that there was publication bias, with a tendency of distribution of odds ratios to one side – usually the “more positive” side, since the “negatives” would not have been published.

**Select studies by means of clear inclusion and exclusion criteria, and evaluate the quality of these studies**

Ideally, two researchers should search and evaluate studies independently. The Kappa statistical test may be used to evaluate the agreement between two researchers. Explain how the disagreements between them were solved, which is usually done by means of an arrangement and based on the opinion of a third experienced researcher. List the characteristics of each primary study and the results of each one clearly. This task can be easier if the study was published according to the STARD (Standards for Reporting of Diagnostic Accuracy – www.consort-statement.org/stardstatement.htm) statement, which was formulated to ensure more clarity, methodological rigor, and the possibility of comparison between the studies of diagnostic methods. Quality issues should be assessed (Table 2).

**Extract data from each study and display them clearly**

Tables of study comparisons are very useful to analyze the clinical and methodological differences between the results (Table 2). Compare studies evaluating age and gender distribution, form of diagnosis or patient selection, relevant covariates, follow-up period, and sample size. In order to obtain the data to be combined, collect the original false and true-positive, false and true-negative values. Occasionally, these data may be estimated from sensitivity and specificity values, as well as from the values of endpoint or reference test occurrence.

**Evaluate heterogeneity among the studies**

Before carrying out the statistical combination (meta-analysis) of the studies, it is fundamental to evaluate the heterogeneity among them. It is important to determine the following:

---

**Graph 3**: Example of an inverted funnel or “Christmas tree” scatterplot. Each point in the plot represents a study with its diagnostic odds ratio and sample size. The shape of a symmetrical funnel suggests the absence of publication bias (in this case, an inverted funnel, also known as “Christmas tree”); it can be displayed with the order of the values in the vertical axis inverted, so it would assume a funnel shape. Asymmetry with study concentration in the right side (the side with higher values of diagnostic odds ratio) suggests publication bias, with less negative studies published.
Table 2 – List of aspects to be checked in the assessment of diagnostic and prognostic studies during the systematic review and meta-analysis

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age and gender distribution of the population studied</td>
<td></td>
</tr>
<tr>
<td>Inclusion date and follow-up period of the study</td>
<td></td>
</tr>
<tr>
<td>Standardized reference test, adequacy of the gold standard chosen, evaluating whether this does not lead to the wrong classification of disease status</td>
<td></td>
</tr>
<tr>
<td>Technical aspects of the performance of the test</td>
<td></td>
</tr>
<tr>
<td>Evaluate the degree of missing data</td>
<td></td>
</tr>
<tr>
<td>Reference values for the gold-standard test and for the index test, in a clear way and representative of the disease of interest</td>
<td></td>
</tr>
<tr>
<td>The confidence interval and the standard error for test accuracy measurements</td>
<td></td>
</tr>
<tr>
<td>The number of readers and their training for the index and the gold-standard test</td>
<td></td>
</tr>
<tr>
<td>Presence of review bias: verify whether the test result in the study was evaluated blind to the endpoints and other tests (independent interpretation).</td>
<td></td>
</tr>
<tr>
<td>Presence of verification bias: the reference test may have been performed preferably in patients with positive tests, which is more frequent when the tests considered as a gold standard are invasive. In this case, the choice of patients for verification by the gold-standard test is not random</td>
<td></td>
</tr>
<tr>
<td>Whether the reference test was performed in all patients. If the index and the gold-standard tests have not been performed in all patients, which is ideal, evaluate whether the choice of patients for the tests was random, thus decreasing the chance of bias</td>
<td></td>
</tr>
<tr>
<td>Presence of clinical spectrum bias: lack of representation of the clinical spectrum of the disease of interest in the study population. Evaluate patients’ demographic and clinical data such as age, gender, race, clinical characteristics, presence of symptoms, disease stage, duration, and comorbidities. The prevalence of the condition among the population studied provides a broader view of the spectrum, circumstances and potential of generalizability.</td>
<td></td>
</tr>
</tbody>
</table>

- Why did the results vary among the studies?
- Was variation random?
- Was variation caused by methodological differences?

To answer these questions, methodological and statistical criteria for the assessment of heterogeneity are required.

Methodological criteria refer to the form of selection, design and comparison of the clinical characteristics of the patients included in each study. Tables demonstrating these aspects are necessary to enable comparison between the studies and should be explicit in the systematic review. From the methodological point of view, the sources of heterogeneity among the studies are many: random, design differences, the form of patient selection, differences in the therapeutic interventions used, and how the tests were evaluated. Another cause of significant heterogeneity that is exclusive of diagnostic and prognostic test studies is the variation in the cut-off points for the reference values of the index test. Heterogeneity may exist even in randomized studies for therapeutic interventions because the randomization was not focused on the index test but rather on the therapeutic intervention. Retrospective studies are weakened because of their risk of selection bias. Verification bias (ascertainment bias, work-up bias) occurs when the indication of the gold-standard test is influenced by the result of the index test: for instance, when the probability of undergoing coronary angiography (“gold standard”) is greater among those with a positive exercise test than among those with a negative test. The analysis of the index test should ideally be blinded to other tests and to the endpoint. The bias caused by the spectrum of disease stages (spectrum bias) leads to variations in the sensitivity and specificity of the index test due to the comparison of populations in different stages of the same disease: some studies with the majority of the patients in a mild and initial stage and other studies with patients in advanced stages of the disease. The methodological aspects to be evaluated are shown in Table 2. The methods used to analyze the statistical heterogeneity of the studies will be addressed in the next topic, with the explanation of the form of combination (meta-analysis) of study results.

**Calculate the results by means of meta-analysis, estimating diagnostic accuracy**

Using meta-analysis, it is possible to provide a pooled summary of the diagnostic accuracy (Table 3). In the electronic address http://www.hrc.es/investigacion/metadisc_en.htm a free software for the performance of meta-analysis of diagnostic or prognostic tests can be found. Other software and specialized programs using a binomial regression model approach based on the likelihood ratio and on the Bayes theorem are available in the electronic address www.mrc-bsu.cam.ac.uk/bugs. These software and specialized programs permit the evaluation of covariates influencing the test accuracy.

The combination methods calculate the weighted means of the study results. These methods are usually divided into two categories: fixed effects and random effects methods.

In the combination using fixed effects methods, each study is given a weight, which is the inverse variance (1/v) of the study. In combination methods with random effects, each study is given a weight, which is the inverse variance added to heterogeneity (1/v + h). In a simplified manner, it is as
Combination of sensitivities and specificities

The methods used for statistical combination of sensitivities and specificities of the studies are the same as those used for comparison of proportions. Sensitivity and specificity of the studies are combined in an integrated value or meta-analysis of studies on diagnostic tests or prognostic factors are shown in Table 3. For each one of the methods, we will also discuss how to evaluate heterogeneity among the studies.

Combination of positive and negative likelihood ratios

The likelihood ratio of a positive test (LR+) measures how much more likely it is for diseased individuals to test positive than non-diseased individuals. The likelihood ratio of a negative test (LR-) measures how much more likely it is for diseased individuals to test negative than non-diseased individuals (Figure 1). Methods of combination of likelihood ratios may be fixed effects methods, such as Mantel-Haenszel or inverted variance, and more frequently random effects methods, such as the DerSimonian and Laird method. The analyses use combinations of likelihood ratios after having applied a log-transform. The combined likelihood ratio has the advantage of permitting the analysis of tests whose result is a continuous variable or with many categories, thus avoiding loss of information when the variable is dichotomized. Another advantage is that, once the test is positive, the post-test odds of the disease may be calculated by the formula: post-test odds = pre-test odds x likelihood ratio. Odds should be converted to probability (c = p/1-o and p = o/1+o – where o expresses odds and p expresses probability). So, the post-test probability = post-test odds/post-test odds + 1 (http://www.cebm.net/index.aspx?o=1043).

Heterogeneity of results of likelihood ratio of the different studies may be evaluated by means of univariate tests, z tests and \( \chi^2 \) test. An interesting method for the evaluation of heterogeneity is the Cochrane’s Q (Q = \( \Sigma w_i(\theta_i - \theta)^2 \), where \( w_i \) is the weight given to the study in the meta-analysis (by sample size, inverse variance, or size of variance), \( \theta \) is the log mean likelihood ratio, and \( \theta \) is the estimate of the log likelihood ratio for each study). The Q value will follow a \( \chi^2 \) distribution under the hypothesis that the likelihood ratio is the same for all studies. Another heterogeneity measurement that can be obtained from this Q value is the I\(^2\) statistic, which is called inconsistency measure and is estimated by the formula:

\[
I^2 = \frac{(Q - g)}{Q} \times 100\%
\]

where df expresses the number of degrees of freedom (number of studies minus one). This statistics describes the percentage of variability of the effect that is due to heterogeneity rather than chance. I\(^2\) values greater than 50% may be considered substantial heterogeneity. Be careful not to mistake the Cochrane’s Q for the evaluation of heterogeneity of likelihood ratio values with the summary statistic Q that will be described below for the global evaluation of the efficacy of a test in a meta-analysis.

<table>
<thead>
<tr>
<th>Table 3 – Forms of summarizing test accuracy by means of meta-analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Combination of sensitivities and specificities</td>
</tr>
<tr>
<td>2. Combination of positive and negative likelihood ratios</td>
</tr>
<tr>
<td>3. Combination of diagnostic odds ratios</td>
</tr>
<tr>
<td>4. Diagnostic effectiveness scores (or effect size measure)</td>
</tr>
<tr>
<td>5. sROC curves (summary ROC or ordinary ROC curve)</td>
</tr>
</tbody>
</table>
Diagnostic odds ratio

The diagnostic odds ratio is a statistical combination of sensitivity, specificity, and positive and negative likelihood ratios. It is not easy to apply in clinical practice, but it is useful for several reasons:

a) It is a statistical measurement of the overall test accuracy;

b) It can be easily obtained from the cross-product of the 2 x 2 table (Figure 1);

c) It is frequently constant, despite the cut-off point used for the test in the different studies;

d) It is useful in the construction of the sROC curve confidence interval, as described below23.

It also expresses the positive likelihood ratio divided by the negative likelihood ratio. The diagnostic odds ratios of each study may be combined by means of fixed effects methods such as Mantel-Haenszel, and random effects methods (DerSimonian and Laird)23. In epidemiological studies for risk factors of rare or uncommon diseases, the value of the odds ratio is close to that of the relative risk. In the case of diagnostic studies, the odds ratios are generally numerically different from the relative risk because positive results are not rare events19.

Diagnostic effectiveness score

The effectiveness score quantifies the degree of overlap of results between diseased and non-diseased individuals, and can be interpreted as the number of standard deviations separating the mean between two distribution curves (diseased and non-diseased individuals, for instance) from results that behave as a continuous variable. It can be obtained by means of a specific calculation formula or from the diagnostic odds ratio21,24. It is the measurement of the standardized distance between the means of two populations - also known as effect size measure or effectiveness measure, which can also be evaluated by means of fixed or random effects models17. It is a quantitative measurement that can be used to compare diagnostic methods or to summarize study outcomes in meta-analyses. For further details on how to obtain it, we suggest Hasselblad and Hedges’ study24, which reviews the method. Like the sROC curve described below, the effectiveness score provides a description of the separation of two distributions of test results (between diseased and non-diseased individuals), regardless of the form of result distribution.

Ordinary or summary ROC curves – sROC curves

Scatterplots can be used to evaluate heterogeneity among the studies. The scatterplot in the ROC space displays the studies in the TPR vs FPR axes (Figure 1). We should note that the ROC curve was created for test results that behave as a continuous variable. However, in this case, each point is the combined result of TPR and FPR of each study. If the studies used different cut-off points, the choice is expected to determine a higher or lower sensitivity. Or else, if the sensitivity and specificity of the studies varied due to implicit causes, influenced by other covariates13, the studies are presumed to supplement each other to illustrate the diagnostic accuracy of the test in different spectra of clinical forms or populations. If in this plot a curvature similar to an ROC curve appears when the points representing the studies are connected, then the difference between the studies is most likely caused by the cut-off point of the reference test value. This is another form of evaluation of the threshold effect19. Mild differences can result from chance, but other types of biases (selection, design, etc.) would presumably increase the variability observed and cause a more scattered configuration of the study representation19. The forest plots and the Galbraith plot also make the visualization of the heterogeneity among studies easier19. Thus, by presenting the studies in graphs or observing the results distribution in the ROC space, an idea of heterogeneity is provided. Additionally, after this evaluation of heterogeneity, the ROC space can be used to construct an adjusted curve that combines (meta-analysis) the study outcomes - the sROC curve as described below.

The sROC curve (ordinary or summary ROC curve) is the estimate of an ordinary ROC curve adjusted for the study outcomes in the ROC space12. The sROC curve is recommended to evaluate the accuracy of a diagnostic test, based on data from a meta-analysis25. We point out the sROC curve as the best option of meta-analysis when there is variation in the cut-off point of the reference test value or when there are implicit or explicit variations in the studies that generate sensitivity and specificity differences13,19,21 (Graph 2). Due to these variations frequently found in this type of study, the mean sensitivity and specificity of the different studies do not reflect the test accuracy adequately13.

The curve can be obtained from the diagnostic odds ratio (described in section “Diagnostic odds ratio”), considering the magnitude of heterogeneity among the studies. The overall diagnostic odds ratio is very robust for heterogeneity and is homogeneous when it does not suffer variations related to the cut-off point of the index test22. The margin of standard error of the curve is adequate when the studies are homogeneous, and was proven to be a reasonable approximation for heterogeneous studies24.

The area under the curve (AUC) and the index Q are useful summaries of the curve13,25. The area under the curve can be used if the assumption that the data present a bilogistic distribution with equal variance is considered, and if there is homogeneity between the studies as regards the estimate of diagnostic odds ratio19. In this case, the Moses11,22 model is used, which restricts the analysis only to the points (studies) located in the region of interest of the ROC space, which theoretically could overestimate the test accuracy and, for this reason, is it not accepted by all authors11. Rutter and Gatsonis’16 proposed methods for the calculation of an sROC curve, taking into consideration the variations between the studies not only by the cut-off threshold, but also by means of hierarchical models13,23. The use of the area under the sROC curve poses the risk of extrapolation beyond the sensitivity and specificity data provided by the studies, unless each study has provided an ROC curve, and that they are really similar19,23,26, because curves with different forms have different areas. There is controversy as to whether or not use weighted models by study variance and sample size (n) for
the construction of the linear regression model that precedes the ROC curve. The best option is to construct both curves (one with weighted models and the other not including the variance and n weight) and compare them. Despite these limitations and theoretical questions, the area under the sROC curve is one of the most robust and useful methods to summarize diagnostic studies data.

As an alternative to globally evaluate the test summarizing the sROC curve, the summary Q measurement is suggested, which evaluates the point of the sROC curve where sensitivity equals specificity. The Q value is invariant to heterogeneity and is quite robust. It is equivalent to the point of symmetry of the ROC curve. The Q measurement, with values between 0.5 and 1.0 (the greater the better), is a global measurement of test efficacy. This summary measure shows how much closer to the north-west rectangle the “curve shoulder” is. If lower than or equal to 0.5, the test does not contribute to the evaluation, and the closer to 1.0, the better the test accuracy. Like the area under the curve, it also evaluates test efficacy globally. If at least ten studies are evaluated, Q distribution is Gaussian (normal).

Assess the effect of variation in study validity on the estimates of diagnostic accuracy

When assessing the internal and external validity of each study and of the combined results, it is necessary to decide how to deal with the heterogeneity found. There are four options to deal with heterogeneity among studies and interpret results variations:

1) Ignoring heterogeneity and using fixed effects methods;
2) Using statistical tests of heterogeneity (which have low sensitivity) and not combining results if heterogeneity is present;
3) Incorporating heterogeneity by using random effects methods; or
4) Explaining the differences by means of analyses of study subgroups or meta-regression, including covariates in the analysis.

Using meta-analysis, it is possible to determine whether the accuracy estimates depend on the characteristics of the study design. Study subgroups are separated according to design characteristics; these subgroups are analyzed separately and together, and an assessment is made on how much the design difference affects the test accuracy. It is also possible to determine whether the diagnostic accuracy is different in subgroups defined by patient or test characteristics by using...
the same technique described. In this manner, it is possible to identify areas for further research.

For instance, a subgroup of studies presents verification bias (when only the test-positives plus the test-negatives with clinically suspected disease undergo the gold-standard method), which frequently underestimates the test. Another subgroup of studies presents review bias (for not evaluating the test blind to the other tests and to endpoints), which tends to overestimate the test. Pooling these studies in quality scores is not always appropriate. They can be analyzed separately by type of methodological flaw, by analyzing how the flaw affects the test accuracy. Thus, the results of overall accuracy measurements can be compared in each subgroup. As such, the effect of the variation of patients and test characteristics on estimates of accuracy can also be assessed.

In comparative meta-analysis of tests, it is fundamental that the tests have been applied to the same patients, or at least that the patients have been randomized to receive each test. However, most of the times, it is unfeasible or unethical to perform all tests or invasive tests in all patients, and this issue is controversial. In the comparison of tests, there are techniques for the construction of sROC curves of the tests alone or in combination, evaluating whether the combination of tests increases the diagnostic or prognostic accuracy.

Interpret the results assessing how much of the meta-analysis can be generalized according to the patients characteristics

Assess how much the results can be generalized according to the clinical characteristics of the patients studied in comparison with the target population in which the meta-analysis was applied, or the relationship between the test accuracy and the year of publication. Decide on possible applications in specific populations. Additionally, generating new hypotheses to be tested is an important contribution.

Comments on the form of publication of the meta-analysis

By analogy with the Quality of Reporting of Meta-analysis (QUOROM) conference for publication of meta-analyses of studies on therapeutic intervention, the methodology should be thoroughly described when publishing the results of meta-analysis of diagnostic and prognostic studies, and each phase of the process should be explicit. The title should identify the study as a meta-analysis or systematic review. The summary should be structured with description of the following aspects: the clinical question, the sources and database, the methods of review and selection of the literature and of quantitative synthesis of the data in a reproducible form, the results with estimates and confidence intervals, and the conclusion with the main results. The introduction should contextualize and provide the background to the objective. The methodology should give details on the sources and search strategies, the period and language, criteria of study selection, form of assessment of publication bias, assessment of quality and methodological validity of the studies, the form of data extraction ideally by two researchers, the study characteristics, the form of assessment of heterogeneity, and the form of mathematically summarizing data. The results should present the review flow according to Figure 2, the study characteristics assessing age and gender distribution, form of diagnosis of patient selection, relevant covariates, follow-up period, sample size (Table 2), and the estimates of diagnostic or prognostic accuracy with the respective confidence intervals. In the discussion, summarize the key issues, discuss the clinical inferences based on the internal and external validity, interpret the results in light of all the evidences, describe the limitations and potential biases - especially publication bias - and suggest further studies.

Conclusion

Systematic reviews of the literature of a clearly formulated question, with a well-planned article search and selection technique, are extremely useful tools in research on diagnostic or prognostic methods. In some cases, it is possible to compile data by means of statistical techniques, thus increasing the power of the estimates of diagnostic accuracy of the test in the primary research. By means of the critical analysis of biases, these techniques provide information that may be useful for the clinical practice and for the formulation of questions to be tested in further studies.

Acknowledgement

The authors thank Prof. Carisi A. Polanczyk, from Universidade Federal do Rio Grande do Sul, for text review and suggestions.

This study was partially funded by Conselho Nacional de desenvolvimento Científico e Tecnológico (CNPq) and by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Capes).

Potential Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Sources of Funding

This study was partially funded by CNPq and CAPES.

Study Association

This article is part of the thesis of Doctoral submitted by Marcos Roberto de Sousa, from Universidade Federal de Minas Gerais.
References


